Re: "cost shifting and timeliness of drug formulary recommendations in atlantic canada," healthcare policy, vol. 5, no. 3, 2010
- PMID: 21804834
- PMCID: PMC2929892
Item in Clipboard
Re: "cost shifting and timeliness of drug formulary recommendations in atlantic canada," healthcare policy, vol. 5, no. 3, 2010
Healthc Policy.
2010 Aug.
No abstract available
Similar articles
-
Cost shifting and timeliness of drug formulary decisions in atlantic Canada.Healthc Policy. 2010 Feb;5(3):100-14. Healthc Policy. 2010. PMID: 21286272 Free PMC article.
-
Drug policy: making effective drugs available without bankrupting the healthcare system.Healthc Pap. 2002;3(1):12-30. doi: 10.12927/hcpap.2002.16906. Healthc Pap. 2002. PMID: 12811107 Review.
-
Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization.Int J Technol Assess Health Care. 2020;36(1):12-19. doi: 10.1017/S0266462319000746. Epub 2019 Dec 3. Int J Technol Assess Health Care. 2020. PMID: 31796132
-
Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.Healthc Pap. 2002;3(1):32-7; discussion 87-94. doi: 10.12927/hcpap.2002.16907. Healthc Pap. 2002. PMID: 12811108 Review.
-
Ontario's formulary committee: how recommendations are made.Pharmacoeconomics. 2003;21(4):285-94. doi: 10.2165/00019053-200321040-00006. Pharmacoeconomics. 2003. PMID: 12600223
References
-
- Grootendorst “Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment.”. PharmacoEconomics. 2002;9(2):79–99. - PubMed
-
- Marra C.A., Lynd L.D., Anis A.H., Esdaile J.M. “Approval Process and Access to Prescription Drugs in Canada.”. Arthritis Care & Research. 2006;55(1):9–11. - PubMed
-
- McMahon M., Morgan S., Mitton C. “The Common Drug Review: A NICE Start for Canada?”. Health Policy. 2006;77(3):339–51. - PubMed
LinkOut - more resources
Full Text Sources
